As CSO, Dr. Basran will lead the translation of ExpressionEdits’ intronization technology into a pipeline of innovative therapeutics, starting with recombinant protein therapeutics. His focus will be on advancing the company’s internal programs from early research through clinical translation, ensuring that its cutting-edge gene optimization platform directly drives the development of next-generation biologic medicines.

"ExpressionEdits has developed a powerful platform that optimizes gene expression in ways previously thought impossible," said Dr. Basran. "I look forward to working with the team to transform this breakthrough into novel therapies that address unmet medical needs."

"Amrik’s extensive experience in biologics development makes him an invaluable addition to ExpressionEdits," said Dr. Kärt Tomberg, CEO and Co-Founder of ExpressionEdits. "His leadership will be key as we expand from platform innovation to therapeutic development, ensuring our technology delivers real impact for patients."

Dr. Basran brings over two decades of experience in biologic drug discovery and development, spanning early-stage research to clinical application. He previously served as Chief Scientific Officer at Avacta Life Sciences, where he led the development of an antibody mimetic scaffold, driving programs from discovery through to large scale manufacturing.  He also held the CSO role at Curadh MTR and was Chief Discovery Officer at Turbine.AI, applying AI-driven approaches to drug discovery.

Earlier in his career, he held senior scientific roles at Domantis and GlaxoSmithKline (GSK), where he was instrumental in the development of domain antibodies and other protein-based therapeutics. His expertise spans biological scaffolds, antibody mimetics, and targeted protein therapies, with experience in half-life extension strategies, targeted radiopharmaceuticals, and novel drug delivery approaches across oncology and inflammatory diseases.

About ExpressionEdits

ExpressionEdits is a pioneering biotechnology company dedicated to enhancing protein expression using advanced AI and proprietary intron technology. Headquartered in Cambridge, UK, ExpressionEdits is committed to advancing genetic medicine through innovative research and development. For more information, visit www.expressionedits.com. 

Contacts:

communications@expressionedits.com